Olivia Sears, et al. ICONIC: Phase 1/2 Trial of ICOS Agonist JTX-2011 Alone and in Combination with Nivolumab (nivo). Presented at the AACR Annual Meeting, April 3, 2017.
Contact Us
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
Eric Laub
(857) 259-3853 elaub@jouncetx.com